You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alimta

Showing 1 - 25 of 383
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Rozzano (Pemetrexed/Carboplatin, Gemcitabine)

Terminated
  • NSCLC
  • Rozzano, Milan, Italy
    Istituto Clinco Humanitas
Sep 8, 2022

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

NSCLC Trial (fianlimab, cemiplimab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Mar 23, 2023

NSCLC Trial in Tampa, Philadelphia (Durvalumab, Carboplatin, Abequolixron)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Tampa, Florida
  • +1 more
Jun 9, 2023

Urothelial Carcinoma, Metastatic Cancer Trial in Houston (Pemetrexed, Zimberelimab, Etrumadenant)

Not yet recruiting
  • Urothelial Carcinoma
  • Metastatic Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Nov 28, 2022

Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Pembrolizumab
  • +7 more
  • (no location specified)
Oct 13, 2022

Tumors Trial (vibostolimab, pembrolizumab, pemetrexed)

Active, not recruiting
  • Neoplasms
  • vibostolimab
  • +6 more
  • (no location specified)
Apr 22, 2022

Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Pembrolizumab coformulated with hyaluronidase
  • +6 more
  • (no location specified)
Jan 27, 2023

Adenocarcinoma of Lung, NSCLC Trial in Rolling Meadows (LP-300, Pemetrexed, Carboplatin)

Not yet recruiting
  • Adenocarcinoma of Lung
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 8, 2022

Lung Cancer Trial in Nashville (Pemetrexed, Gemcitabine)

Completed
Has Results
  • Lung Cancer
  • Nashville, Tennessee
    Tennessee Oncology
Feb 21, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

Recruiting
  • Lung Cancer
  • AMG 510
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation Trial (Pembrolizumab, Pemetrexed,

Withdrawn
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Mar 14, 2022

NSCLC Metastatic Trial in Salt Lake City (Durvalumab, Pemetrexed, Carboplatin)

Recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Mar 1, 2022

Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc Trial in Stanford (Durvalumab, Carboplatin, Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Stanford, California
    Stanford University
Oct 27, 2022

NSCLC Trial in Washington, Hackensack, Neptune (Nivolumab, Ipilimumab, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Washington, District of Columbia
  • +2 more
Jan 27, 2023

Metastatic Non Small Cell Lung Cancer Trial in Japan (Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed)

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Datopotamab Deruxtecan
  • +4 more
  • Fukuoka, Japan
  • +3 more
Jan 13, 2023

Lung Cancer, NSCLC, PD-L1 Gene Mutation Trial in Detroit (Durvalumab, Carboplatin, Pemetrexed)

Withdrawn
  • Lung Cancer
  • +3 more
  • Detroit, Michigan
    Henry Ford Health System
Feb 15, 2022

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Bronx, New York

Completed
Has Results
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bronx, New York
  • +2 more
Oct 18, 2021

Advanced Cancers Trial in Houston (Crizotinib (Xalkori), Pazopanib, Pemetrexed)

Terminated
  • Advanced Cancers
  • Crizotinib (Xalkori)
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 3, 2021